Clinical Trial Update: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of everolimus (RAD001) in adults with angiomyolipoma associated with tuberous sclerosis complex or sporadic lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis
• Tuberous Sclerosis Complex

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) | Phase 3 | Status: COMPLETED | Results posted: 2012-08-28